STOCK TITAN

[Form 4] Vor Biopharma Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Vor Biopharma (VOR) reported insider sales on a Form 4 by Reprogrammed Interchange LLC, attributed to director Reid Hoffman. The transactions occurred on October 1–3, 2025 and were executed in multiple trades at weighted-average prices within a disclosed range of $36.82 to $42.70. Following the reported sales, the filing shows 1,597,308 shares beneficially owned, held directly. The share figures reflect a 1-for-20 reverse stock split effected on September 18, 2025. The filing notes Hoffman may be deemed a beneficial owner through shared control of Reprogrammed and disclaims ownership except to his pecuniary interest.

Vor Biopharma (VOR) ha riportato vendite da insider su un modulo Form 4 da Reprogrammed Interchange LLC, attribuite al direttore Reid Hoffman. Le operazioni si sono svolte dal 1 al 3 ottobre 2025 e sono state eseguite in moltepliche operazioni a prezzi ponderati all'interno di un intervallo divulgato di 36,82 $ a 42,70 $. Dopo le vendite riportate, la pratica indica 1.597.308 azioni detenute beneficiariamente, possedute direttamente. Le cifre delle azioni riflettono una reverse stock split di 1 contro 20 effettuata il 18 settembre 2025. La pratica nota che Hoffman potrebbe essere considerato un proprietario beneficiario mediante controllo condiviso di Reprogrammed e nega la proprietà salvo il proprio interesse pecuniario.

Vor Biopharma (VOR) reportó ventas de insiders en un Formulario 4 por Reprogrammed Interchange LLC, atribuidas al director Reid Hoffman. Las operaciones ocurrieron entre el 1 y el 3 de octubre de 2025 y se ejecutaron en múltiples operaciones a precios ponderados dentro de un rango divulgado de $36.82 a $42.70. Tras las ventas reportadas, el archivo muestra 1,597,308 acciones poseídas de forma beneficiosa, mantenidas directamente. Las cifras de acciones reflejan un dividendo inverso de 1 por 20 efectuado el 18 de septiembre de 2025. El archivo señala que Hoffman puede ser considerado un propietario beneficioso a través del control compartido de Reprogrammed y niega la propiedad excepto por su interés pecuniario.

Vor Biopharma (VOR)은 Reid Hoffman 이사에게 귀속되는 Reprogrammed Interchange LLC의 Form 4에 의한 내부자 매도를 보고했다. 거래는 2025년 10월 1일부터 3일까지에 걸쳐 여러 건의 거래로 수행되었으며, 공개된 범위 내에서 가중평균가로 $36.82에서 $42.70 사이의 가격으로 체결되었다. 보고된 매도 이후, filing에 직접 보유된 이익 소유 주식 수 1,597,308주가 기재되어 있다. 이 수치는 2025년 9월 18일에 시행된 1대 20의 역분할 반영된 것이다. 서류는 Hoffman이 Reprogrammed의 공동 지배를 통해 잠재적 소유자로 간주될 수 있으며, 금전적 이해관계 이외의 소유권은 포기한다고 명시한다.

Vor Biopharma (VOR) a signalé des ventes d'initiés sur un formulaire Form 4 par Reprogrammed Interchange LLC, attribuées au administrateur Reid Hoffman. Les opérations ont eu lieu du 1er au 3 octobre 2025 et ont été exécutées en plusieurs transactions à des prix moyens pondérés dans une plage divulguée de $36,82 à $42,70. Suite aux ventes déclarées, le dossier indique 1 597 308 actions détenues de manière bénéficiaire, détenues directement. Les chiffres d'actions reflètent une réorganisation inverse de 1 pour 20 effectuée le 18 septembre 2025. Le dossier note que Hoffman peut être considéré comme bénéficiaire par le biais du contrôle partagé de Reprogrammed et dénie la propriété sauf à son intérêt pécuniaire.

Vor Biopharma (VOR) meldete Insider-Verkäufe in einem Formular 4 durch Reprogrammed Interchange LLC, dem Direktor Reid Hoffman zugeordnet. Die Transaktionen fanden am 1. bis 3. Oktober 2025 statt und wurden in mehreren Trades zu gewichteten Durchschnittspreisen innerhalb eines offengelegten Bereichs von $36,82 bis $42,70 ausgeführt. Nach den gemeldeten Verkäufen zeigt die Einreichung 1.597.308 Aktien, die direkt gehalten werden, als profitieren Eigentum. Die Aktienzahlen spiegeln einen 1-für-20 Reverse Stock Split wider, der am 18. September 2025 durchgeführt wurde. Die Einreichung bemerkt, Hoffman könne durch gemeinsame Kontrolle von Reprogrammed als wirtschaftlich Berechtigter gesehen werden und bestreitet Eigentum außer seinem finanziellen Interesse.

فور بيوفارما (VOR) أبلغت عن مبيعات داخلية في نموذج 4 بواسطة شركة Reprogrammed Interchange LLC، المنسوبة إلى المدير ريد هوفمان. وقعت المعاملات من 1 إلى 3 أكتوبر 2025 وتم تنفيذها في عدة صفقات بأسعار متوسطة الوزن ضمن نطاق معلن عنه من $36.82 إلى $42.70. عقب المبيعات المبلغ عنها، يظهر الملف وجود 1,597,308 سهم مملوكة لفائدة مباشرة، مملوكة مباشرة. تعكس أعداد الأسهم إجراء تقسيم عكسي للسهم بواقع 1 مقابل 20 قد تم في 18 سبتمبر 2025. يذكر الملف أن هوفمان قد يعتبر مالكاً مستفيداً من خلال السيطرة المشتركة على Reprogrammed وينفي الملكية باستثناء مصلحته المالية.

Vor Biopharma (VOR) 在 Form 4 上报告了 Reprogrammed Interchange LLC 的内部人出售,归于董事 Reid Hoffman。交易发生于 2025年10月1日至3日,以在披露范围内的加权平均价分多笔执行,价格区间为 $36.82 至 $42.70。据报告的出售之后,备案显示直接持有的 1,597,308 股受益所有权。这些股数反映了在 2025年9月18日 实施的 1 比 20 的股票拆分。备案指出 Hoffman 可能通过对 Reprogrammed 的共同控制被视为受益所有人,并除其金钱利益外,否认所有权。

Positive
  • None.
Negative
  • None.

Insights

Routine Form 4 detailing multi-day insider sales with post‑trade holdings.

The filing records sales by Reprogrammed Interchange LLC, with attribution to director Reid Hoffman. Prices are reported as weighted averages for trades executed across price ranges, which is typical when multiple fills occur the same day. The remaining beneficial ownership shown is 1,597,308 shares after the listed transactions.

The share counts reflect a 1-for-20 reverse stock split effective September 18, 2025, ensuring comparability of amounts. Ownership is reported as direct, with a standard disclaimer that Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest in Reprogrammed.

These disclosures are administrative and do not specify proceeds use or strategic changes. Actual impact on float or trading depends on market absorption and holder activity disclosed in subsequent filings, if any.

Vor Biopharma (VOR) ha riportato vendite da insider su un modulo Form 4 da Reprogrammed Interchange LLC, attribuite al direttore Reid Hoffman. Le operazioni si sono svolte dal 1 al 3 ottobre 2025 e sono state eseguite in moltepliche operazioni a prezzi ponderati all'interno di un intervallo divulgato di 36,82 $ a 42,70 $. Dopo le vendite riportate, la pratica indica 1.597.308 azioni detenute beneficiariamente, possedute direttamente. Le cifre delle azioni riflettono una reverse stock split di 1 contro 20 effettuata il 18 settembre 2025. La pratica nota che Hoffman potrebbe essere considerato un proprietario beneficiario mediante controllo condiviso di Reprogrammed e nega la proprietà salvo il proprio interesse pecuniario.

Vor Biopharma (VOR) reportó ventas de insiders en un Formulario 4 por Reprogrammed Interchange LLC, atribuidas al director Reid Hoffman. Las operaciones ocurrieron entre el 1 y el 3 de octubre de 2025 y se ejecutaron en múltiples operaciones a precios ponderados dentro de un rango divulgado de $36.82 a $42.70. Tras las ventas reportadas, el archivo muestra 1,597,308 acciones poseídas de forma beneficiosa, mantenidas directamente. Las cifras de acciones reflejan un dividendo inverso de 1 por 20 efectuado el 18 de septiembre de 2025. El archivo señala que Hoffman puede ser considerado un propietario beneficioso a través del control compartido de Reprogrammed y niega la propiedad excepto por su interés pecuniario.

Vor Biopharma (VOR)은 Reid Hoffman 이사에게 귀속되는 Reprogrammed Interchange LLC의 Form 4에 의한 내부자 매도를 보고했다. 거래는 2025년 10월 1일부터 3일까지에 걸쳐 여러 건의 거래로 수행되었으며, 공개된 범위 내에서 가중평균가로 $36.82에서 $42.70 사이의 가격으로 체결되었다. 보고된 매도 이후, filing에 직접 보유된 이익 소유 주식 수 1,597,308주가 기재되어 있다. 이 수치는 2025년 9월 18일에 시행된 1대 20의 역분할 반영된 것이다. 서류는 Hoffman이 Reprogrammed의 공동 지배를 통해 잠재적 소유자로 간주될 수 있으며, 금전적 이해관계 이외의 소유권은 포기한다고 명시한다.

Vor Biopharma (VOR) a signalé des ventes d'initiés sur un formulaire Form 4 par Reprogrammed Interchange LLC, attribuées au administrateur Reid Hoffman. Les opérations ont eu lieu du 1er au 3 octobre 2025 et ont été exécutées en plusieurs transactions à des prix moyens pondérés dans une plage divulguée de $36,82 à $42,70. Suite aux ventes déclarées, le dossier indique 1 597 308 actions détenues de manière bénéficiaire, détenues directement. Les chiffres d'actions reflètent une réorganisation inverse de 1 pour 20 effectuée le 18 septembre 2025. Le dossier note que Hoffman peut être considéré comme bénéficiaire par le biais du contrôle partagé de Reprogrammed et dénie la propriété sauf à son intérêt pécuniaire.

Vor Biopharma (VOR) meldete Insider-Verkäufe in einem Formular 4 durch Reprogrammed Interchange LLC, dem Direktor Reid Hoffman zugeordnet. Die Transaktionen fanden am 1. bis 3. Oktober 2025 statt und wurden in mehreren Trades zu gewichteten Durchschnittspreisen innerhalb eines offengelegten Bereichs von $36,82 bis $42,70 ausgeführt. Nach den gemeldeten Verkäufen zeigt die Einreichung 1.597.308 Aktien, die direkt gehalten werden, als profitieren Eigentum. Die Aktienzahlen spiegeln einen 1-für-20 Reverse Stock Split wider, der am 18. September 2025 durchgeführt wurde. Die Einreichung bemerkt, Hoffman könne durch gemeinsame Kontrolle von Reprogrammed als wirtschaftlich Berechtigter gesehen werden und bestreitet Eigentum außer seinem finanziellen Interesse.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 S 1,400 D $39.1925(1) 1,637,660(2)(3) D
Common Stock 10/02/2025 S 4,937 D $37.2057(4) 1,632,723(3) D
Common Stock 10/02/2025 S 1,513 D $38.3771(5) 1,631,210(3) D
Common Stock 10/02/2025 S 7,700 D $39.5728(6) 1,623,510(3) D
Common Stock 10/02/2025 S 13,001 D $40.1282(7) 1,610,509(3) D
Common Stock 10/02/2025 S 5,300 D $42.319(8) 1,605,209(3) D
Common Stock 10/03/2025 S 3,200 D $37.3731(9) 1,602,009(3) D
Common Stock 10/03/2025 S 4,701 D $38.1444(10) 1,597,308(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Hoffman Reid

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $39.11 to $39.415. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
2. The number of shares beneficially owned reflects the 1-for-20 reverse stock split effected September 18, 2025.
3. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
4. This transaction was executed in multiple trades at prices ranging from $36.82 to $37.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. This transaction was executed in multiple trades at prices ranging from $37.85 to $38.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. This transaction was executed in multiple trades at prices ranging from $39.20 to $39.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
7. This transaction was executed in multiple trades at prices ranging from $39.86 to $40.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
8. This transaction was executed in multiple trades at prices ranging from $42.00 to $42.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
9. This transaction was executed in multiple trades at prices ranging from $36.88 to $37.69. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
10. This transaction was executed in multiple trades at prices ranging from $38.00 to $38.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Reid Hoffman 10/03/2025
/s/ Frank Huang, Manager of Reprogrammed Interchange LLC 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

VOR Latest News

VOR Latest SEC Filings

VOR Stock Data

211.17M
5.49M
39.09%
43.63%
15.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE